270 related articles for article (PubMed ID: 30180865)
21. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
Höring E; Montraveta A; Heine S; Kleih M; Schaaf L; Vöhringer MC; Esteve-Arenys A; Roué G; Colomer D; Campo E; Ott G; Aulitzky WE; van der Kuip H
Br J Haematol; 2017 May; 177(4):557-561. PubMed ID: 28295185
[TBL] [Abstract][Full Text] [Related]
22. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
23. Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1.
Jiang Z; Zhang A; Wei W; Li S
Sci Rep; 2023 May; 13(1):8389. PubMed ID: 37225761
[TBL] [Abstract][Full Text] [Related]
24. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
25. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
26. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
[TBL] [Abstract][Full Text] [Related]
27. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
28. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.
Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S
Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404
[TBL] [Abstract][Full Text] [Related]
29. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
[TBL] [Abstract][Full Text] [Related]
30. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
31. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
[TBL] [Abstract][Full Text] [Related]
32. Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.
Dal Col J; Mastorci K; Faè DA; Muraro E; Martorelli D; Inghirami G; Dolcetti R
Cancer Res; 2012 Apr; 72(7):1825-35. PubMed ID: 22311672
[TBL] [Abstract][Full Text] [Related]
33. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
[TBL] [Abstract][Full Text] [Related]
36. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Jung HJ; Chen Z; McCarty N
Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
[TBL] [Abstract][Full Text] [Related]
37. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
39. PRDM1 is required for mantle cell lymphoma response to bortezomib.
Desai S; Maurin M; Smith MA; Bolick SC; Dessureault S; Tao J; Sotomayor E; Wright KL
Mol Cancer Res; 2010 Jun; 8(6):907-18. PubMed ID: 20530581
[TBL] [Abstract][Full Text] [Related]
40. Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]